Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1982 Sep;77(1):69–73. doi: 10.1111/j.1476-5381.1982.tb09270.x

Effects of lysine-vasopressin and oxytocin on central cardiovascular control.

L D Tran, J L Montastruc, P Montastruc
PMCID: PMC2044654  PMID: 7126997

Abstract

1 The cardiovascular effects of intravenous and intracisternal administration of neurohypophysial peptides were compared in dogs anaesthetized with chloralose. 2 Intravenous lysine-vasopressin (0.1 to 100 mu/kg) induced a dose-dependent increase in blood pressure and a decrease in heart rate. In contrast, intracisternal lysine-vasopressin (0.01 to 10 mu/kg induced a dose-related decrease in blood pressure and did not change heart rate. 3 Intracisternal oxytocin (1 and 10 mu/kg) increased blood pressure and did not change heart rate, whereas the same doses injected intravenously were inactive. 4 Pretreatment with guanethidine (15 mg/kg i.v. 24 h beforehand) abolished the hypotensive responses to intracisternal vasopressin but not the pressor action of intravenous vasopressin. 5 The pressor responses to central injections of oxytocin were not modified by guanethidine. 6 Hypotension elicited by intracisternal vasopressin was probably due to a decrease in sympathetic tone whereas the hypertension induced by intracisternal oxytocin was independent of variations in sympathetic tone.

Full text

PDF
69

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonaccio M. J., Kerwin L., Taylor D. G. Reductions in blood pressure, heart rate and renal sympathetic nerve discharge in cats after the central administration of muscimol, a GABA agonist. Neuropharmacology. 1978 Oct;17(10):783–791. doi: 10.1016/0028-3908(78)90065-5. [DOI] [PubMed] [Google Scholar]
  2. Brownstein M. J. Peptidergic pathways in the central nervous system. Proc R Soc Lond B Biol Sci. 1980 Oct 29;210(1178):79–90. doi: 10.1098/rspb.1980.0120. [DOI] [PubMed] [Google Scholar]
  3. Chalmers J. P. Brain amines and models of experimental hypertension. Circ Res. 1975 Apr;36(4):469–480. doi: 10.1161/01.res.36.4.469. [DOI] [PubMed] [Google Scholar]
  4. Chelly J., Kouyoumdjian J. C., Mouillé P., Huchet A. M., Schmitt H. Effects of L-glutamic acid and kainic acid on central cardiovascular control. Eur J Pharmacol. 1979 Nov 23;60(1):91–94. doi: 10.1016/0014-2999(79)90055-4. [DOI] [PubMed] [Google Scholar]
  5. Cowley A. W., Jr, Monos E., Guyton A. C. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res. 1974 Apr;34(4):505–514. doi: 10.1161/01.res.34.4.505. [DOI] [PubMed] [Google Scholar]
  6. Galosy R. A., Clarke L. K., Vasko M. R., Crawford I. L. Neurophysiology and neuropharmacology of cardiovascular regulation and stress. Neurosci Biobehav Rev. 1981 Spring;5(1):137–175. doi: 10.1016/0149-7634(81)90040-3. [DOI] [PubMed] [Google Scholar]
  7. Liard J. F., Dériaz O., Tschopp M., Schoun J. Cardiovascular effects of vasopressin infused into the vertebral circulation of conscious dogs. Clin Sci (Lond) 1981 Sep;61(3):345–347. doi: 10.1042/cs0610345. [DOI] [PubMed] [Google Scholar]
  8. Montastruc J. L., Montastruc P. Effect of intracisternal application of 6-hydroxydopamine on the antihypertensive action of propranolol in the dog. Eur J Pharmacol. 1980 May 2;63(2-3):103–116. doi: 10.1016/0014-2999(80)90434-3. [DOI] [PubMed] [Google Scholar]
  9. Möhring J., Kintz J., Schoun J. Studies on the role of vasopressin in blood pressure control of spontaneously hypertensive rats with established hypertension (SHR, stroke-prone strain). J Cardiovasc Pharmacol. 1979 Nov-Dec;1(6):593–608. doi: 10.1097/00005344-197911000-00001. [DOI] [PubMed] [Google Scholar]
  10. Möhring J., Schoun J., Kintz J., McNeil R. Decreased vasopressin content in brain stem of rats with spontaneous hypertension. Naunyn Schmiedebergs Arch Pharmacol. 1980;315(1):83–84. doi: 10.1007/BF00504234. [DOI] [PubMed] [Google Scholar]
  11. Padfield P. L., Brown J. J., Lever A. F., Morton J. J., Robertson J. I. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med. 1981 Apr 30;304(18):1067–1070. doi: 10.1056/NEJM198104303041803. [DOI] [PubMed] [Google Scholar]
  12. Padfield P. L., Brown J. J., Lever A. F., Morton J. J., Robertson J. I. Changes of vasopressin in hypertension: Cause or effect? Lancet. 1976 Jun 12;1(7972):1255–1257. doi: 10.1016/s0140-6736(76)91734-7. [DOI] [PubMed] [Google Scholar]
  13. Philippu A. Involvement of cholinergic systems of the brain in the central regulation of cardiovascular functions. J Auton Pharmacol. 1981 Sep;1(4):321–330. doi: 10.1111/j.1474-8673.1981.tb00462.x. [DOI] [PubMed] [Google Scholar]
  14. Sofroniew M. V., Weindl A. Projections from the parvocellular vasopressin- and neurophysin-containing neurons of the suprachiasmatic nucleus. Am J Anat. 1978 Nov;153(3):391–429. doi: 10.1002/aja.1001530305. [DOI] [PubMed] [Google Scholar]
  15. Varma S., Jaju B. P., Bhargava K. P. Mechanism of vasopressin-induced bradycardia in dogs. Circ Res. 1969 Jun;24(6):787–792. doi: 10.1161/01.res.24.6.787. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES